drugset / Trial / NCT07184788
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory/Relapsed Aggressive B-Cell Lymphoma.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2030-10-01
- Completion
- 2031-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | 30 mg | — |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | Intravenous |